TGX.NYSE 10X Genomics Trend Cloud Study Potential 100% Upside.
Updated
10X Genomics Trend Cloud Study shows a Potential 100% Upside.
This Ticker is way oversold and a Double Bottom is Seen.
Very Risky and Speculative. I'm Nibbling a few $100.
As always, please get a few outside Expert's Advice before making Trade or Investment Decisions.
Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away.
Regards Graham.
This Ticker is way oversold and a Double Bottom is Seen.
Very Risky and Speculative. I'm Nibbling a few $100.
As always, please get a few outside Expert's Advice before making Trade or Investment Decisions.
Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away.
Regards Graham.
Note
As normal will need a Catalyst OR RISK ON Sentiment. As Said I'm nibbling on this one. Should there be a FED rate Cut the down Momentum will Reverse IMO. I'm currently in a small loss scenario - however it's important to be patient and try not to destroy ones Capital. I'm Holding for Now and will watch till a potential Rate Cut.Note
Holding for now. Has performed worse than anticipated. Conviction is Required.
Note
On My Chart this on a Wave -9 Down.Due for a reversal soon as very oversold.
However my strategy is WAIT.
Note
Buy.Canaccord Genuity Adjusts Price Target on 10x to $32 From $50, Maintains Buy Rating.
Note
The Japanese Carry Trade Has Distorted Many Stocks and Trades.
I did Dip Buy a Few $ in anticipation.
Note
10x Genomics Executives Sell Shares to Cover their Tax Obligations.
Paying Tax via Share Options is normal and expected.
Holding.
Note
10x Genomics Price Target Announced at $35 a Share by Leerink Partners.Note
10x Genomics Price Target Maintained With a $30 a Share by Stephens & Co.
Volatile Markets.
Difficult to buy now. but Holding.
Note
Remember to always set your Stop Loss at a reasonable value to maintain ones capital. Adobe is an example.Note
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead. Shares Tank.Note
Nasty One.
10x Genomics Price Target Cut to $20 a Share From $32 by Canaccord Genuity.
Canaccord Genuity now moved Down on my Ranking to 30% Reliable. Which is Useless IMO.
Trade active
Recent JFKJ to Health Minister by Trump and his Stance on Vaccines shows a sell.
I'm Out.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.